Skip to content

RISK ANALYSIS AND MANAGEMENT FOR MEDICATION OPTIMIZATION IN THE PREOPERATIVE AND POSTOPERATIVE PERIOD OF CARDIAC SURGICAL PATIENTS

RISK ANALYSIS AND MANAGEMENT FOR MEDICATION OPTIMIZATION IN THE PREOPERATIVE AND POSTOPERATIVE PERIOD OF CARDIAC SURGICAL PATIENTS

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05210335
Enrollment
200
Registered
2022-01-27
Start date
2019-11-01
Completion date
2021-06-30
Last updated
2022-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Surgery, Clinical Pharmacy, Drug Related Problems, Risk Assesment

Keywords

Drug related problems, Clinical pharmacy, Cardiac surgery, Risk assesment

Brief summary

Optimal perioperative and long-term success in cardiac-surgery require precise management of drug treatment. This study was aimed to determine prevalence, types and associated factors of drug related problems (DRPs) at both preoperative and postoperative stages in patients at cardiac-surgery by using risk analysis method.

Detailed description

Cardiac surgery becomes a life-saving option in patients once medical treatments become inadequate. In order to achieve optimal perioperative and long- term success in cardiac surgery, drug treatment should be managed precisely. Patients with cardiovascular diseases are at risk for developing drug related problems (DRPs) due to polypharmacy and having received high-alert medications, such as antiarrhythmics or antithrombotic agents. In addition, type of operation (multiple artery bypass or combined valve procedures), existence of chronic atherosclerotic diseases (such as diabetes mellitus, hypertension), length of stay (LOS) at hospital, frailty, changes in medications for unstable cardiac conditions, incomplete or inadequate history for medication at hospital admission, transition between wards by different healthcare teams and transfer of discrepancies throughout entire perioperative period contributes to increased risk of DRPs in patients at cardiac surgery. It has been shown that over one third of patients suffer from DRPs during hospitalization. Clinical pharmacists are in a position to identify and prevent DRPs, therefore can help to provide optimal pharmaceutical treatment by performing medication reconciliation, improving patient compliance, monitoring of laboratory values and conducting patient education for surgical patients.However, there is limited information about prevalence and risk factors of DRPs in patients at cardiac surgery, in particular with perioperative stages. Majority of studies regarding DRPs have been conducted in specific populations such as elderly, pediatrics or in general medicine. Therefore this study was aimed to determine prevalence, types and associated factors of drug related problems (DRPs) at both preoperative and postoperative stages in patients at cardiac-surgery by using risk analysis method.

Interventions

OTHERClinical pharmacist's recommendation to physicians about drug related problems

Clinical pharmacist's recommendation to physicians about drug related problems

Sponsors

Hacettepe University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients are aged 18 years or older * admitted to the hospital for a planned elective cardiac surgery during the study period were considered eligible.

Exclusion criteria

* Patients who refused to participate, * transferred from different wards * have urgent surgery planned were excluded

Design outcomes

Primary

MeasureTime frameDescription
Obtaining drug related problems preoperative and postoperative periods6 months (1 November 2019-30 March 2020)Obtaining valid drug related problems and their characteristic is the primary outcome as a part of the risk analysis.
Building risk analysis model3 months (30 March 2020-30 June 2020)In line with the valid drug related problems expert panel build the model
Obtaining clinical pharmacist affect6 months (1 August 2020- 30 January 2021)Obtaining clinical pharmacist affect as a part of the risk analysis model

Secondary

MeasureTime frameDescription
Obtaining clinical pharmacist intervention on other factors6 months (1 August 2020- 30 January 2021)the affect of this model on quality of life, nutritional status, fraility status, hospital mortality rate, length of hospital stay, lenght of intensive care unit stay.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026